ABI3 and thyroid gland carcinoma: We then evaluated the methylation status of CpG sites located at R1 region in two additional thyroid carcinoma cell lines (FTC 236 and FTC 133), which the expression of ABI3 was increased following treatment with 5-aza-dC (Figure 1A).